Clinical research studies

We currently support a number of clinical research studies, including:

  • ASCOT – investigating the potential of an anti-inflammatory treatment (triamcinolone acetonide) to improve the outcome of surgery in eyes that have suffered severe trauma
  • IIH-WT –  A randomised controlled trial of bariatric surgery versus a commercial community weight loss programme for the sustained treatment of Idiopathic Intracranial Hypertension
  • LEROS –  aims to find out more about the effectiveness and safety of the study drug (Raxone) in the long-term treatment of Leber’s hereditary optic neuropathy (LHON)
  • IRISS – An open label, registry study of the safety of ILUVIEN® (fluocinolone acetonide 190 micrograms intravitreal implant in applicator)
  • ODAK – aims to provide a safe and effective drug for the treatment of the rare ocular disease Acanthamoeba keratitis (AK) tested according to international regulatory standards
  • Using computers to assess visual function in adults & children
  • GILEAD – aims to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis in participants failing treatment for active noninfectious uveitis
  • DIAMONDS – aims to determine whether currently used standard lasers and the newer technology of subthreshold micropulse laser are equal or whether one is better than the other
  •  Motivations and barriers to participating in ophthalmology research projects
For more information about these studies please contact Emma Columbine on 0161 276 3432


  • ARGUS II Retinal Stimulation System – investigating if a new device can partially replace the function of the retina in patients whose retina is badly damaged and cannot be repaired 
  • ARGUS II Retinal Prosthesis System Dry AMD – aims to test if the ARGUS II device is safe in patients whose retina is damaged due to Age-related macular degeneration and if it improves sight
  • RAINBOW – An extension study to evaluate the long term efficacy and safety of Ranibizumab compared with laser therapy for the treatment of infants born prematurely with retinopathy of prematurity
  • KERALINK – aims to establish whether Corneal Cross Linking (CXL) is safe and effective in stabilizing the progression of keratoconus in children and young patients between the ages of 10 and 16 years.
For more information about these studies please contact Fiona Crawford on 0161 276 5615


  • AZURE – aims to find out more about the effectiveness of two different therapy regimes for Aflibercept after the first year of treament for patients suffering from neo-vascular age related macular degeneration (nAMD)
For more information about this study please contact Afeefa Rasheeth 01617017692


  • SUMMIT – aims to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma
  • HYDRUS IV – aims to assess the safety and effectiveness of the Hydrus implant for lowering intraocular pressure in glaucoma patients undergoing cataract surgery
  • TAGS – comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
  • EDNA (early detection) – designed for patients who are being treated for wet AMD in one eye, but whose other is not currently affected. The aim is to determine the effectiveness of different diagnostic techniques on the untreated eye
  • FASBAT –  Observing Fibrosis, Macular Atrophy and Sub retinal Highly Reflective Material – Before and After Intervention with AntiVEGF Treatment. (An extension to the EDNA Study)
For more information about these studies please contact Raisa Platt on 0161 701 0446


  • CFI Study – aims to identify patients with advanced dry AMD (geographic atrophy), low blood CFI levels together with CFI mutations
  • DRAKO – A non-interventional study to assess the effectiveness of aflibercept in routine clinical practice in patients with visual impairment due to diabetic macular oedema (DMO)
  • TERRA – designed to compare the clinical efficacy and cost-effectiveness of the treat and extend regime compared with a PRN regime for neovascular age related macula degeneration
  • SIGHT – looking at the association between the geographic atrophy phenotype of AMD and low CFI protein levels and CFI gene variants in patients suffering with the dry form of AMD.
  • XEN-45 ACG – evaluating the safety and IOP-lowering effectiveness of the XEN implant in patients suffering with Angle Closed Glaucoma.
  • EuPatch – The Role of Glasses Wearing in Amblyopia Treatment
For more information about these studies please contact Stephanie Clarke on 0161 701 2589


  • EMERALD – to determine the diagnostic performance and cost-effectiveness of a new form of surveillance (ophthalmic grader pathway) for people with stable DMO and/or PDR
  • PanOptica – to assess the safety and tolerability of PAN-90806 Eye Drops, Suspension in treatment-naïve participants with AMD and assess the biological response to treatment with PAN-90806 Eye Drops, Suspension.
For more information about these studies please contact Charlene Hyde on 0161 701 0848


  • EMU – A data collection and analysis pilot study to indicate preliminary characterisation of the electromyogram signal in relation to needle position with respect to the extraocular muscles, as observed during electromyogram needle guided treatment of strabismus in adults
  • STAR – aims to find out if vision in patients suffering from Chorodieremia can be preserved  using an Adeno-Associated Viral Vector (AAV2) encoding Rab Escort Protein 1 (REP1) using gene therapy
  • XIRIUS – investigating if vision in patients suffering from XLRP can be preserved by replacing the defective RPGR gene using gene therapy
For more information about these studies please contact Rebecca Pad on 0161 701 6205


For more information about this study please contact Khaled Alzahrani